Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O75223

UPID:
GGCT_HUMAN

ALTERNATIVE NAMES:
Cytochrome c-releasing factor 21

ALTERNATIVE UPACC:
O75223; B2RDN0; B8ZZN4; B8ZZR8; Q9BS37

BACKGROUND:
The enzyme Gamma-glutamylcyclotransferase, known alternatively as Cytochrome c-releasing factor 21, is crucial for maintaining glutathione levels and inducing apoptosis through cytochrome c release from mitochondria. This underscores its significant role in cellular health and survival mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Gamma-glutamylcyclotransferase offers promising avenues for therapeutic intervention. Given its central role in glutathione regulation and apoptosis, targeting this protein could lead to innovative treatments for conditions associated with oxidative stress and cell death.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.